Hear from Imperial College London’s Psychedelic Research Team, as they share their discoveries and insights from the groundbreaking Psilocybin for Depression studies, Psilodep 1 and Psilodep 2. Leonie Schneider, a study participant on Psilodep 2, will share her personal story of healing and transformation. 

The psychedelic research represents one of the most critical initiatives in psychiatry and brain science in recent decades. It indicates incredible promise for treating severe mental health conditions, including depression, PTSD and addiction. We will explore hopes for the future of psychedelic therapy and risks of mass-adoption of psychedelics. 

Psilodep 1 explored the use of psilocybin to treat individuals suffering from Treatment-Resistant Depression (TRD). Psilodep 2 clinically led by Dr Rosalind Watts, compares Psychedelic Assisted Therapy with antidepressant medication (SSRIs), Escitalopram. This landmark study explores how these treatments differ in their effects on the brain, and how effective they both are at reducing depression symptoms, and increasing connectedness and wellbeing in individuals suffering from Major Depressive Disorder (MDD).